Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
170 USD | +0.87% | +5.20% | +9.46% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.46% | 298B | |
+45.83% | 754B | |
+40.95% | 630B | |
-5.75% | 352B | |
+20.15% | 331B | |
+18.83% | 250B | |
+12.08% | 217B | |
-0.53% | 216B | |
+6.62% | 164B | |
+0.30% | 163B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190